

23<sup>rd</sup> October, 2023

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2023**

The Presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2023 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

Encl : A/a

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,  
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com



## Q2 FY 2023-24

Revenues: Summary



# Revenue: Summary

Revenues (Rs cr)	Q2 FY24	Q2 FY23	Gr%
India	1,444	1224	18%
United States	248	292	-15%
Germany	266	220	21%
Brazil	252	185	36%
Other countries	280	239	17%
Others	170	131	30%
<b>Total</b>	<b>2,660</b>	<b>2,291</b>	<b>16%</b>

